N/A N=9 Seizure Activity in Alzheimer's Disease
Alzheimer's Disease · Seizures
Primary: Number of Participants With Evaluable fMRI Scans — 9; 9; 9; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
Seizure · Epilepsy · Cerebral Malaria
Primary: Freedom From Seizure — 7 individuals
N/A N=31 Cognitive Effects of Treatment of Interictal Discharges
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Phase 2 N=147 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Phase 2 N=34 Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Alzheimer's Disease
Primary: Changes in Executive Function as Measured by the NIH EXAMINER Computer Battery — -0.06; -0.14 score on a scale — p=0.55
N/A N=14 Tolerability and Efficacy of Depakote-extended Release in the Elderly
Elderly · Epilepsy · Seizures
Primary: Effectiveness of Medication as Measured by Participation Through the End of the Trial. — 14 participants
Phase 4 N=102 A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
Epilepsy With Partial On-set Seizures
Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants
Phase 3 N=893 Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications
Status Epilepticus
Primary: Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given — 329; 282 participants — p=<0.001
Phase 4 N=38 Treatments for Psychogenic Nonepileptic Seizures (NES)
Convulsion, Non-Epileptic · Conversion Disorder · Depression
Primary: Number of Nonepileptic Seizures (NES) — 5.0; 6.0; 3.0; 6.0 seizures — p=0.29
Phase 4 N=24 Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
Epilepsy
Primary: MMSE at Baseline and at Three (3) Months. — 18.2; 2.2 units on a scale — p=.01
N/A N=19 Drug Exposure Registry for GSK2248761, an Investigational NNRTI
HIV Infections
Primary: Number of Participants With Occurrence of Seizure — 0; 1 Participants
N/A N=12 Lactic Acidosis During and After Seizures
Epilepsy
Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L
Phase 2 N=44 A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM
Seizure · Epilepsy · Cerebral Malaria
Primary: Minutes With Seizure on EEG — 165.2; 464.8 minutes with seizure
Phase 3 N=509 Pregabalin Versus Levetiracetam In Partial Seizures
Partial Seizures
Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants
N/A N=44 Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims
Cardiac Arrest
Primary: Percentage of Seizure-positive and Seizure-negative That Were Correctly Classified by the SEDline in All Evaluated Cases — 100 percentage of seizures
Phase 2 N=106 Efficacy of Intravenous Levetiracetam in Neonatal Seizures
Neonatal Seizures
Primary: Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg) — 15; 24 Participants — p=<0.001
Phase 4 N=158 IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
Tonic-clonic Seizure
Primary: Number of Participants Who Experienced a Recurrent Seizure After Treatment. — 2; 3 participants
Phase 4 N=103 Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
Phase 2 N=125 Anti-epileptogenic Effects of Eslicarbazepine Acetate
Post Stroke Epilepsy
Primary: Proportion of Patients Who Experience the First Unprovoked Seizures (US) Within the First 6 Months After Randomisation (Failure Rate) — 2; 7; 3; 0 Participants
N/A N=12,386 Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…
Phase 2 N=12 Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Glioma, Malignant · Surgery · Seizures
Primary: Peritumoral HFO Rate — 2.5; 1.4 HFOs per minute
N/A N=10 Treating Non-epileptic Seizures Using Magnetic Brain Stimulation
Nonepileptic Seizures
Primary: Number of Weekly Psychogenic Non-epileptic Seizure-events — 6.9; 5.3 events
Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
N/A N=31 Seizure Detection and Automatic Magnet Mode Performance Study
Epilepsy
Primary: Summary of Seizures Reported by Investigators and Triple Review — 87; 124; 211; 82 Seizures
Phase 4 N=52 Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
Traumatic Brain Injury · Subarachnoid Hemorrhage
Primary: Seizure Incidence — 5; 3 Participants
N/A N=199 Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
Epilepsy
Primary: Responders: Number of Subjects With a 50% or Greater Reduction in Seizure Frequency — 138; 44; 17 participants
Phase 2 N=31 Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
Epilepsy, Partial
Primary: Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period — -30.88 percentage of change
Phase 3 N=100 Randomized Therapy In Status Epilepticus
Status Epilepticus
Primary: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE — 79.59…
Phase 2 N=7 PF-06372865 in Subjects With Photosensitive Epilepsy
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale